Provided by Tiger Trade Technology Pte. Ltd.

Corvus Pharmaceuticals

14.01
-0.0600-0.43%
Post-market: 14.00-0.0100-0.07%19:51 EDT
Volume:1.11M
Turnover:15.88M
Market Cap:1.17B
PE:-26.43
High:15.06
Open:14.10
Low:13.98
Close:14.07
52wk High:26.95
52wk Low:2.54
Shares:83.77M
Float Shares:67.20M
Volume Ratio:0.58
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5300
EPS(LYR):-0.5320
ROE:-32.60%
ROA:-38.36%
PB:19.17
PE(LYR):-26.33

Loading ...

Corvus Pharmaceuticals Inc - 75% Achieved Easi 75, 25% Easi 90, 33% Iga 0/1

THOMSON REUTERS
·
Jan 20

Corvus Pharmaceuticals Announces Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis

Reuters
·
Jan 17

Corvus Pharmaceuticals to Announce Results From Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS
·
Jan 17

BRIEF-Corvus To Announce Results From Cohort 4 Of Placebo-Controlled Phase 1 Clinical Trial

Reuters
·
Jan 05

Corvus Pharmaceuticals to Announce Phase 1 Soquelitinib Atopic Dermatitis Trial Results in January 2026

Reuters
·
Jan 05

Corvus Pharmaceuticals Confirms Plans to Announce Results From Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference

THOMSON REUTERS
·
Jan 05

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

GlobeNewswire
·
Dec 08, 2025

Corvus Pharmaceuticals Reports Positive Q3 Earnings Call

TIPRANKS
·
Nov 06, 2025

Stock Track | Corvus Pharmaceuticals Plummets 5.63% Following Q3 Net Loss Report

Stock Track
·
Nov 05, 2025

Corvus Pharmaceuticals Shares Down 2.1% After Co Reports Q3 Net Loss

THOMSON REUTERS
·
Nov 05, 2025

H.C. Wainwright Sticks to Its Buy Rating for Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
Nov 05, 2025

Corvus Pharmaceuticals reports third quarter 2025 financial results

Reuters
·
Nov 05, 2025

BRIEF-Corvus Pharmaceuticals Q3 EPS USD -0.12

Reuters
·
Nov 05, 2025

Corvus Pharma Q3 EPS $(0.12) Beats $(0.14) Estimate

Benzinga
·
Nov 05, 2025

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

GlobeNewswire
·
Nov 03, 2025

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Simply Wall St.
·
Nov 01, 2025

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire
·
Oct 31, 2025

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

GlobeNewswire
·
Oct 29, 2025

Corvus Pharmaceuticals’ Phase 3 Study on Soquelitinib: A Potential Game-Changer in Lymphoma Treatment

TIPRANKS
·
Oct 28, 2025

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

GlobeNewswire
·
Oct 17, 2025